Drig Trial
Janssen says combination Phase III study for immunotherapy Darzalex for multiple myeloma shows significant PFS
June 6, 2016Research and Development, Sales and Marketing ASCO, Drig Trial, Janssen, multiple myeloma
Janssen said combination late stage trials for its immunotherapy drug to treat multiple myeloma showed 61% progression-free survival. The company …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
